Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | short review

Optimal follow-up of endometrial cancer patients

verfasst von: MD, PhD Eduard Vrdoljak, MD, PhD Tihana Boraska Jelavić, MD, PhD Branka Petrić Miše

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Gynecological malignancies account round 10 % of all female cancers, with the uterine cancer being the most predominant one. Surveillance programs of all gynecologic cancers are primarily based on recurrence rates, timing of recurrence, salvage options and chances for cure of patient with recurrence. Since there is no prospective, high evidence data about optimal surveillance program after primary treatment of patients with endometrial cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including comprehensive gynecological examination, still contribute to the greatest number of recurrence detection. Radiologic tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to the estimated risk of relapse for individual patient.
Literatur
1.
Zurück zum Zitat Creutzberg CL, van Putten WLJ, Koper PCM, et al. for the PORTEC Study Group. Surgery and radiotherapy versus surgery alone for patients with stage –1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11. CrossRefPubMed Creutzberg CL, van Putten WLJ, Koper PCM, et al. for the PORTEC Study Group. Surgery and radiotherapy versus surgery alone for patients with stage –1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11. CrossRefPubMed
2.
Zurück zum Zitat Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51. CrossRefPubMed Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51. CrossRefPubMed
3.
Zurück zum Zitat Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23. CrossRefPubMed Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23. CrossRefPubMed
4.
Zurück zum Zitat Ben Arie A, Lavie O, Gdalevich M, et al. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. Eur J Surg Oncol. 2012;38(2):166–9. CrossRefPubMed Ben Arie A, Lavie O, Gdalevich M, et al. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. Eur J Surg Oncol. 2012;38(2):166–9. CrossRefPubMed
5.
Zurück zum Zitat Simpkins F, Papadia A, Kunos C, et al. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular invasion. Int J Gynecol Cancer. 2013;23(1):98–104. CrossRefPubMed Simpkins F, Papadia A, Kunos C, et al. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular invasion. Int J Gynecol Cancer. 2013;23(1):98–104. CrossRefPubMed
6.
Zurück zum Zitat Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520–9. CrossRefPubMed Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol. 2006;101:520–9. CrossRefPubMed
7.
Zurück zum Zitat Milgrom SA, Kollmeier MA, Abu-Rustum NR, O’Cearbhaill RE, Barakat RR, Alektiar KM. Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol 2014;134:297–301. http://​dx.​doi.​org/​10.​1016/​j.​ygyno.​ Accesssed: 13 May 2014. CrossRefPubMed Milgrom SA, Kollmeier MA, Abu-Rustum NR, O’Cearbhaill RE, Barakat RR, Alektiar KM. Quantifying the risk of recurrence and death in stage III (FIGO 2009) endometrial cancer. Gynecol Oncol 2014;134:297–301. http://​dx.​doi.​org/​10.​1016/​j.​ygyno.​ Accesssed: 13 May 2014. CrossRefPubMed
8.
9.
Zurück zum Zitat Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129:478–85. CrossRefPubMed Ayeni TA, Bakkum-Gamez JN, Mariani A, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecol Oncol. 2013;129:478–85. CrossRefPubMed
10.
Zurück zum Zitat Sartori E, Pasinetti B, Chiudinelli F, et al. Surveillance procedures for patients treated for endometrial cancer: a review of the literature. In J Gynecol Cancer. 2010;20(6):985–92. CrossRef Sartori E, Pasinetti B, Chiudinelli F, et al. Surveillance procedures for patients treated for endometrial cancer: a review of the literature. In J Gynecol Cancer. 2010;20(6):985–92. CrossRef
11.
Zurück zum Zitat Sartori E, Lafare B, Gadducci a, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003;13:458–65. CrossRefPubMed Sartori E, Lafare B, Gadducci a, et al. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003;13:458–65. CrossRefPubMed
12.
Zurück zum Zitat Moschiano EJ, Barbuto DA, Walsh C, et al. Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol. 2014;33:268–73. CrossRefPubMed Moschiano EJ, Barbuto DA, Walsh C, et al. Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; vaginal versus other sites. Int J Gynecol Pathol. 2014;33:268–73. CrossRefPubMed
13.
Zurück zum Zitat Gaducci A, Cosio S, Fanucci A, Cristofani R, Genazzani AR. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res. 2000;20:1977–84. Gaducci A, Cosio S, Fanucci A, Cristofani R, Genazzani AR. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res. 2000;20:1977–84.
14.
Zurück zum Zitat Salani R, Backes FJ, Fung Kee Fung M Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466–78. CrossRefPubMed Salani R, Backes FJ, Fung Kee Fung M Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466–78. CrossRefPubMed
15.
Zurück zum Zitat Smith CJ, Heeren M, Nicklin JL, et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol. 2007;107:124–9. CrossRefPubMed Smith CJ, Heeren M, Nicklin JL, et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol. 2007;107:124–9. CrossRefPubMed
16.
Zurück zum Zitat Tjalma WAA, Van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the coseffectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer. 2004;14:931–7. CrossRefPubMed Tjalma WAA, Van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the coseffectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer. 2004;14:931–7. CrossRefPubMed
17.
Zurück zum Zitat Aung L, Howells RE, Lim KC, Hudson E, Jones PW. Why routine clinical follow-up for patients with early stage endometrial cancer is not always necessary: a study on women in South Wales. Int J Gynecol Cancer. 2014;24:556–63. CrossRefPubMed Aung L, Howells RE, Lim KC, Hudson E, Jones PW. Why routine clinical follow-up for patients with early stage endometrial cancer is not always necessary: a study on women in South Wales. Int J Gynecol Cancer. 2014;24:556–63. CrossRefPubMed
18.
Zurück zum Zitat Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013;131(3):609–12. CrossRefPubMed Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ. Post treatment surveillance of type II endometrial cancer patients. Gynecol Oncol. 2013;131(3):609–12. CrossRefPubMed
19.
Zurück zum Zitat Carrara L, Gadducci A, Landoni F, et al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer. 2012;22(6):1013–9. CrossRefPubMed Carrara L, Gadducci A, Landoni F, et al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer. 2012;22(6):1013–9. CrossRefPubMed
20.
Zurück zum Zitat Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):33–8. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(6):33–8.
21.
Zurück zum Zitat Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. Can Med Assoc. 1997;157:879–86. Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. Can Med Assoc. 1997;157:879–86.
22.
Zurück zum Zitat Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006;103:709–13. CrossRefPubMed Bristow RE, Purinton SC, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006;103:709–13. CrossRefPubMed
23.
Zurück zum Zitat Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer. 2005;15:413–9. CrossRefPubMed Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer. 2005;15:413–9. CrossRefPubMed
24.
Zurück zum Zitat Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000;95:692–6. CrossRefPubMed Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000;95:692–6. CrossRefPubMed
25.
Zurück zum Zitat Kadkhodayan S, Shahriari S, Treglia G, Yousefi Z, Sadeghi R. Accuracy of 18-F-FDG PET imaging in the follow-up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;128(2):397–404. CrossRefPubMed Kadkhodayan S, Shahriari S, Treglia G, Yousefi Z, Sadeghi R. Accuracy of 18-F-FDG PET imaging in the follow-up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2013;128(2):397–404. CrossRefPubMed
26.
Zurück zum Zitat Ozcan Kara P, Kara T, Kaya Bm Kara Gedik G, Sari O. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Rev Esp Med Nucl Imagen Mol. 2012;31(5):257–60. PubMed Ozcan Kara P, Kara T, Kaya Bm Kara Gedik G, Sari O. The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker. Rev Esp Med Nucl Imagen Mol. 2012;31(5):257–60. PubMed
27.
Zurück zum Zitat Kitajima K, Suzuki K, Nakamoto Y, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Radiol. 2012;81:3557–62. CrossRefPubMed Kitajima K, Suzuki K, Nakamoto Y, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Radiol. 2012;81:3557–62. CrossRefPubMed
28.
Zurück zum Zitat Testa AC, Legge A D, Virgilio B, et al. Which imaging technique should we use in the follow-up of gynaecological cancer? Best Pract Res Clin Obstet Gynaecol 2014;28:769–91 CrossRefPubMed Testa AC, Legge A D, Virgilio B, et al. Which imaging technique should we use in the follow-up of gynaecological cancer? Best Pract Res Clin Obstet Gynaecol 2014;28:769–91 CrossRefPubMed
29.
Zurück zum Zitat Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum Ca 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994;84:12–6. PubMed Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum Ca 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol. 1994;84:12–6. PubMed
30.
Zurück zum Zitat Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58(1):24–38. CrossRefPubMed Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58(1):24–38. CrossRefPubMed
Metadaten
Titel
Optimal follow-up of endometrial cancer patients
verfasst von
MD, PhD Eduard Vrdoljak
MD, PhD Tihana Boraska Jelavić
MD, PhD Branka Petrić Miše
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0202-z

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe